Life Sciences

Siemens patent filings climb, but quality over quantity is the name of the game  

The German industrial and manufacturing company recently topped the charts as the number one filer at the EPO. A look at its portfolio shows a focus on innovation and high-value assets

Siemens patent filings climb, but quality over quantity is the name of the game  
15 Mar 2019

With PTAB petition 10,000 approaching, the US patent system has spawned a $1 billion industry

The signing of the America Invents Act changed the face of US patent practice in a way that very few who steered the legislation through Congress had anticipated

15 Mar 2019

Proposed US legislation aimed at patent thickets unlikely to boost biologics competition

The Biologic Patent Transparency Act seeks to accelerate biosimilar entry, but leaves key litigation issues unaddressed and would confer only marginal benefits on imitators

Latest

View all
15 Mar 2019

Bangalore’s top tech firms offer qualified praise for patent office progress

Heading toward elections, the Indian government is touting its record on IP system reforms. Rights holders acknowledge progress but say they have concerns about patent quality Read more

14 Mar 2019

New research highlights impact of patent eligibility uncertainty on life sciences and tech investments

Academic calls for Congress to act on 101 “to restore investor confidence” with private equity and VC players clear that doubts over patentability make it less likely they will part with cash Read more

12 Mar 2019

Europe’s patent landscape in six charts 

The EPO’s annual report for 2018 was published today and shows that filing levels are up, grants have surged, the US leads, China slows and Siemens is number one Read more

11 Mar 2019

Operating companies ramp up their US patent deal-making, but NPEs see big drop

Microsoft and Facebook feature among leaders as transactions involving software assets in Q4 of 2018 hit highest level since 2010 Read more

News

View all
11 Mar 2019

The big life sciences patent news from February

Our round-up of the major IP developments in the sector, including the US’s first biosimilars and unclean hands suits, a big CRISPR grant for UCal, a controversial SPC move in Europe, biopharma Brexit concerns, cannabis patent u-turn in Thailand and much more Read more

6 Mar 2019

The state of play in the global IP market

IAM's annual benchmarking survey is designed to identify the key concerns of senior decision makers in areas such as deal-making, valuation, patent office performance, top litigation venues and policy  Read more

18 Feb 2019

Rolling the dice on eligibility

Congressional action is the only way to solve the uncertainty on section 101 of the US patent statute, argues Aaric Eisenstein of Personalised Media Communications Read more

18 Feb 2019

Patent deals show how Indian startups can benefit from multinational research activity

An AI health-tech startup recently named one of the world's most promising had its roots in the re-organisation of Xerox's research centre in India Read more

Analysis

View all
8 Mar 2019

CJEU asked to resolve long-standing SPC marketing authorisation conundrum

Europe’s highest court has never ruled on whether certificates can be acquired on the basis of a third-party marketing approval – a practice that has given rise to disputes between biopharma innovators Read more

26 Feb 2019

Two years of trade war spotlight have done little to change views of IP environment in China

But American Chamber of Commerce in China survey does reveal that IP concerns are affecting US firms' business plans, and ‘cautious pessimism’ is the new normal Read more

25 Feb 2019

Stockpiling of SPC-protected drugs by generics set to be allowed in the EU

Legislative disputes over the nature of a proposed manufacturing waiver have been resolved paving the way for implementation of controversial new regime Read more

22 Feb 2019

Pharma still dominates in Israel, but Big Tech also likes what it sees

The Start-Up Nation is widely recognised for its contributions to the life sciences industries. However, patent analysis shows why global technology players are also going shopping there Read more